FFG Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.8M Buy
9,869
+5,978
+154% +$6.11M 3.36% 14
2026
Q1
$3.58M Buy
+3,891
New +$3.94M 1.42% 18
2025
Q3
Sell
-30,446
Closed -$23.7M 40
2025
Q2
$23.7M Buy
30,446
+9,590
+46% +$7.45M 7.89% 3
2025
Q1
$17.2M Buy
20,856
+783
+4% +$652K 7.09% 6
2024
Q4
$15.5M Buy
20,073
+3,022
+18% +$2.5M 5.43% 7
2024
Q3
$15.1M Buy
17,051
+5,020
+42% +$4.51M 5.23% 7
2024
Q2
$10.9M Sell
12,031
-86
-0.7% -$68.8K 4.29% 11
2024
Q1
$9.43M Buy
12,117
+69
+0.6% +$49.1K 3.91% 11
2023
Q4
$7.02M Buy
+12,048
New +$7.03M 3.75% 12

Other funds holding LLY

FFG Partners's LLY Position: Q2 2026 in Review

FFG Partners increased its Eli Lilly (LLY) stake by 154% in Q2 2026, buying an estimated $6.11M and bringing the position to 9,869 shares worth $11.8M. The position accounts for 3.36% of the portfolio, ranked #14.

FFG Partners first reported a position in LLY in Q4 2023 and has held it in 9 quarters since. The position peaked at $23.7M in Q2 2025. 1,746 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • FFG Partners held 9,869 shares of Eli Lilly worth $11.8M as of Q2 2026.
  • FFG Partners bought 5,978 Eli Lilly shares in Q2 2026, an estimated $6.11M.
  • Eli Lilly made up 3.36% of FFG Partners's portfolio in Q2 2026, its #14 holding.
  • FFG Partners first reported a position in Eli Lilly in Q4 2023 and has held it in 9 quarters since.
  • FFG Partners's Eli Lilly position peaked at $23.7M in Q2 2025.
  • 1,746 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on FFG Partners's 13F filing for Q2 2026, filed 9 Jul 2026.